John Hall is an investment analyst in the U.S. Equity Division, working with the health care team on the analysis of drug pipelines and existing therapeutic agents. John is a vice president of T. Rowe Price Group, Inc. He is also a vice president and an Investment Advisory Committee member of the Heath Sciences and Small-Cap Stock Funds.
Die drei Innovationstreiber bei Biotechaktien
John Hall, 2021/09/27 23:00:00.000